Overview

A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is selecting second line therapy for patients with pancreatic cancer using molecular profiling will improve 1 year survival.
Phase:
Phase 2
Details
Lead Sponsor:
Translational Drug Development
Collaborators:
American Association for Cancer Research
Scottsdale Healthcare
Stand Up To Cancer